Clonazepam (Rivotril) Dosing for Anxiety
For generalized anxiety and panic disorder, start clonazepam at 0.25-0.5 mg twice daily and titrate gradually to an effective dose of 1-2 mg/day in divided doses, with a maximum of 4 mg/day if needed.
Initial Dosing Strategy
The evidence strongly supports a conservative start-low, go-slow approach:
- Starting dose: 0.25-0.5 mg twice daily (or 0.5 mg at bedtime)
- Target therapeutic range: 1-2 mg/day in divided doses
- Titration schedule: Increase by 0.25-0.5 mg every 3-7 days based on response and tolerability
A landmark dose-response study 1 demonstrated that 1 mg/day is the minimum effective dose for panic disorder, with doses of 1-2 mg/day offering the optimal balance between therapeutic benefit and tolerability. Higher doses (3-4 mg/day) showed no additional efficacy but increased side effects like somnolence and ataxia.
Disorder-Specific Considerations
Panic Disorder
The research consistently shows efficacy at relatively modest doses. In a controlled trial 2, a fixed dose of 2 mg/day achieved panic-free status in 61.5% of patients versus 11.1% with placebo. The mean effective dose across studies ranges from 1.9-2.4 mg/day 1, 3.
Social Anxiety Disorder
For social phobia, the evidence supports similar dosing. A double-blind study 4 found a mean maximum dose of 2.4 mg/day (range 0.5-3 mg) achieved a 78.3% response rate versus 20% with placebo. Benefits were apparent as early as week 1-2.
Generalized Anxiety
When combined with antidepressants for various anxiety disorders, clonazepam demonstrated comparable efficacy to other benzodiazepines but with significantly fewer adverse events (26.7% vs 48.4% for alprazolam and 43.9% for lorazepam) 5.
Special Population Adjustments
Elderly or debilitated patients: Start at 0.25 mg once or twice daily, with slower titration. The NICE guidelines 6 recommend maximum doses of 2 mg/24 hours in elderly patients for anxiety management, compared to 4 mg/24 hours in younger adults.
Patients with medical comorbidities: Use lower starting doses (0.25 mg) and increase cautiously, particularly in those with respiratory insufficiency, liver disease, or risk of falls 7.
Critical Safety Considerations
Tolerance and Dependence
Benzodiazepines carry risks of tolerance, addiction, depression, and cognitive impairment with regular use 8. However, clonazepam's longer half-life may provide more stable blood levels and potentially less interdose anxiety compared to shorter-acting agents.
Discontinuation Protocol
When stopping clonazepam after intermediate to long-term use, taper by 0.25 mg per week once reaching 1 mg/day, preceded by 0.5 mg reductions every 2 weeks at higher doses 9. This gradual taper minimizes withdrawal symptoms (anxiety, tremor, insomnia, sweating) and maintains clinical improvement.
Contraindications and Warnings
- Avoid in severe pulmonary insufficiency, severe liver disease, and myasthenia gravis 7
- Increased fall risk, especially in elderly patients
- Paradoxical agitation occurs in approximately 10% of patients 8
- Can cause or worsen delirium 7
- May exacerbate sleep-disordered breathing 10
Combination Therapy Considerations
When used adjunctively with SSRIs (the preferred first-line treatment for most anxiety disorders 11), clonazepam can provide rapid symptom relief during the 4-8 week SSRI onset period. The benzodiazepine can then be tapered once the antidepressant reaches full effect.
Avoid combining with high-dose olanzapine due to reports of fatalities from oversedation and respiratory depression 7.
Practical Prescribing Algorithm
- Week 0-1: Start 0.25-0.5 mg twice daily (0.25 mg if elderly/frail)
- Week 1-2: Assess response; if inadequate and well-tolerated, increase to 0.5 mg twice daily
- Week 2-4: Target 1-2 mg/day in divided doses (the therapeutic sweet spot)
- Week 4+: If needed, cautiously increase to maximum 4 mg/day, though doses above 2 mg rarely provide additional benefit
- Ongoing: Reassess need for continued treatment every 3-6 months; plan taper if stable >1 year
The evidence does not support routine use above 2 mg/day for most anxiety presentations, as higher doses increase adverse effects without proportional benefit 1.